Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
Takanori Numata,Jun Araya,Hanae Miyagawa,Keitaro Okuda,Yu Fujita,Hirofumi Utsumi,Daisuke Takekoshi,Mitsuo Hashimoto,Shunsuke Minagawa,Takeo Ishikawa,Hiromichi Hara,Kazuyoshi Kuwano
DOI: https://doi.org/10.2147/JAA.S311975
2021-06-03
Journal of Asthma and Allergy
Abstract:Takanori Numata, Jun Araya, Hanae Miyagawa, Keitaro Okuda, Yu Fujita, Hirofumi Utsumi, Daisuke Takekoshi, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Kazuyoshi Kuwano Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Correspondence: Takanori Numata Tel +81-3-3433-1111 (ex 3271) Fax +81-3-3433-1020 Email Background: In Japan, biologic therapy was initiated for patients with severe asthma in 2009. In recent years, four biologics with different mechanisms of action have become available in the clinical setting. However, the efficacy of switching between biologics remains uncertain. Methods: To elucidate the efficacy of switching between biologics, 97 patients were enrolled who had received any biologic therapy for severe asthma at Jikei University Hospital, Tokyo, Japan, from July 2009 to December 2020. We retrospectively examined the patient characteristics, biomarkers, pulmonary function test results, selected biologics, and efficacy. Results: Thirty-one males and 66 females received any biologics. The mean age was 53.3 years at the initiation of biologic therapy. Initially, 33, 41, 15 and eight patients received omalizumab, mepolizumab, benralizumab, and dupilumab, respectively. Among three representative indicators for biologics administration, the peripheral blood eosinophil count, serum IgE levels and fractional exhaled nitric oxide, 64% of the patients had two indicators, and 28% had three indicators. Thirty-four patients (35%) switched from the initial biologic to another, and the reasons for switching included persistent asthmatic symptoms (n=22), schedule of hospital visits (n=5), and other reasons. Thus, the treatment was effective in 11 patients after switching. In addition, two patients received combination therapy with different biologics. Eighteen patients (19%) interrupted treatment for various reasons. Regardless of whether the biologic was the initial therapy, the overall efficacy of the four biologics was 60% based on the global evaluation of treatment effectiveness. Conclusion: Switching between biologics can be a promising option for severe asthma patients in whom treatment with an initial biologic is ineffective. Keywords: benralizumab, dupilumab, mepolizumab, omalizumab, switching Bronchial asthma is a common and chronic respiratory disease affecting 300 million people worldwide 1 and approximately 5–10% of Japanese adults. 2 , 3 The prevalence of severe refractory asthma among adults with asthma is 3% to 10%. 4 Recent elucidation of the molecular mechanisms involved in the pathogenesis of asthma has led to the development of novel biologic therapies. Omalizumab is the first anti-IgE antibody biologic approved to treat asthma. It was reported to be effective in 60% of patients with severe atopic asthma 5 and became available in 2009 in Japan. Subsequently, mepolizumab, an anti-interleukin (IL)-5 antibody, became available in 2016. Benralizumab, an anti-IL-5 receptor antibody, and dupilumab, an anti-IL-4 receptor antibody, became available in 2018. These treatments were found to be effective for severe asthma. 6–12 Additionally, these biologics target the components of type 2 inflammation, and predictive biomarkers for each biologic have been reported. However, these predictive markers can overlap between biologics, and other factors can affect the selection of the first-line treatment in the clinical setting. Thus, multiple biologics may be effective in any given patient, particularly in those positive for several predictive biomarkers. Therefore, we conducted a retrospective study to clarify the following outcomes: the effectiveness of switching biologics in real-world setting (primary endpoint); the clinical characteristics and biomarkers to predict the efficacy of biologics (secondary endpoint). From July 2009 to December 2020, 97 Japanese patients with severe asthma received any biologics at least once at Jikei University Hospital, Tokyo, Japan. All the asthma patients were diagnosed by respiratory physicians based on the Japanese guidelines 3 or the Global Initiative of Asthma (GINA) guidelines. 13 Severe asthma was defined as requiring a high dose of inhaled corticosteroids (ICSs) plus at least one of the following additional control measures: long-acting β-2 agonists (LABAs), long-acting muscarinic antagonists (LAMAs), leukotriene receptor antagonists (LTRAs), a xanthine derivative and daily -Abstract Truncated-
immunology,allergy,respiratory system